Skip to main content

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at https://aems.tga.gov.au/

Adverse events can also be reported to Mundipharma at Drugsafety@mundipharma.com.au

Report adverse event Login Register

country

country

AU

Australia (AU)
Brazil (BR)
France (FR)
Germany (DE)
Italy (IT)
Japan (JP)
Spain (ES)
United Kingdom (UK)

Therapy Areas
Medicines
Resources
About Us

Report adverse event

country

country

AU

Australia (AU)
Brazil (BR)
France (FR)
Germany (DE)
Italy (IT)
Japan (JP)
Spain (ES)
United Kingdom (UK)

Name

Surname

Your Email?

Reason for contact

Type your message here

* Required Fields

Leave this field blank

Report Adverse Event

Adverse events should be reported. Reporting forms and information can be found at https://aems.tga.gov.au/

Adverse events can also be reported to Mundipharma at Drugsafety@mundipharma.com.au

Forgot your password?

Please enter the email that you used to register to Napp HCP portal.

We will send you an email to reset your password.

Enter your registered email address

Email

Enter your email address which was provided during registration

Leave this field blank

If you cannot find the confirmation email in your inbox, it is worth checking in your spam or junk section.

country

country

AU

Australia (AU)
Brazil (BR)
France (FR)
Germany (DE)
Italy (IT)
Japan (JP)
Spain (ES)
United Kingdom (UK)

Therapy Areas
Medicines
Resources
About Us

CONTACT US
LEGAL
COOKIE POLICY
PRIVACY

Therapy Areas
Medicines
Resources
About Us

Copyright Mundipharma Pharmaceuticals. All Rights Reserved. | JOB CODE: AU-NPR-2200022 | Prepared: April 2022

STAY CONNECTED

Opioid Charter

Opioid Charter For Mundipharma's Charter on the responsible medical use of opioid analgesics in pain management Click Here..

Opioid Safety Statement

"Attention should be given as the use of opioids has a risk of addiction, misuse and abuse. Therefore, appropriate assessment and monitoring is required at initiation, maintenance and tapering down of opioid therapy."